JMP Securities Reiterates Market Outperform on Athira Pharma, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a Market Outperform rating on Athira Pharma (NASDAQ:ATHA) and maintained a price target of $19.
June 20, 2024 | 2:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst Jason Butler has reiterated a Market Outperform rating on Athira Pharma and maintained a price target of $19.
The reiteration of a Market Outperform rating and a maintained price target of $19 by JMP Securities is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100